Last updated: February 20, 2026
What is the Drug and Its Current Market Position?
NDC 12496-1212 is a formulation of Opdivo (nivolumab), a programmed death-1 (PD-1) immune checkpoint inhibitor. It is approved for multiple cancer indications, including melanoma, non-small cell lung cancer (NSCLC), and bladder cancer.
As of 2023, Opdivo maintains a leading market share among immunotherapies for oncology. It is marketed by Bristol-Myers Squibb and has a broad indication portfolio. The global market for PD-1 inhibitors was valued at approximately USD 12.5 billion in 2022, with Opdivo accounting for about 35% of sales.
Market Dynamics and Competitive Landscape
| Aspect |
Details |
| Market Size (2022) |
USD 12.5 billion (global PD-1/PD-L1 inhibitors) |
| Leading Drugs |
Opdivo (Bristol-Myers Squibb), Keytruda (Merck), Libtayo (Regeneron, Sanofi) |
| Key Indications |
Melanoma, NSCLC, head and neck cancers, bladder, other solid tumors |
| Market Share (2022) |
Opdivo: ~35%, Keytruda: ~55% |
Opdivo's competitive advantage stems from earlier FDA approval for multiple indications and ongoing trial expansion. Patents extend into the late 2020s, with biosimilar competition expected post-2030.
Patent and Regulatory Outlook
The last key patent in the U.S. for Opdivo expiring in 2028[1], with potential for patent extensions. Regulatory decisions are ongoing in non-oncology indications, including in colorectal and gastric cancers.
Pricing and Reimbursement
Average wholesale prices (AWP) are estimated at USD 6,400–USD 9,200 per month per patient, with actual reimbursement often lower due to negotiated discounts and value-based pricing agreements. The price per dose can vary by country and indication.
Revenue and Financial Projections
| Year |
Estimated Global Revenue |
Notes |
| 2023 |
USD 4.5 billion |
Based on sales growth of 8% from 2022 |
| 2025 |
USD 6.0 billion |
Continued expansion of indications and geographic penetration |
| 2030 |
USD 8.5 billion |
Post-patent expiration, assuming biosimilars emerge and market remains competitive |
Market growth will be driven by approval expansion, particularly into earlier lines of therapy and maintenance settings. The increase in combination therapies with other immune checkpoint inhibitors or chemotherapy enhances revenue prospects.
Price Projection Scenarios
| Scenario |
Assumptions |
Price per Dose |
Revenue Outlook (2023–2030) |
| Conservative |
Negligible biosimilar impact, stable pricing |
USD 8,000 |
USD 4.5–5.0 billion annually |
| Moderate |
Biosimilars gain limited market share (~20%) by 2030 |
USD 6,500 |
USD 4.0–6.0 billion, market share shifting to biosimilars |
| Aggressive |
Biosimilars significantly erode market share (~50%) by 2030, price drops to USD 4,000 |
USD 4,000 |
USD 2.5–4.0 billion |
Biosimilar Competition Impact
After patent expiry, biosimilars are projected to enter the market within 18–24 months. Price reductions are estimated at 25%–50%. The reduction in market price would significantly affect Opdivo's revenue, especially in mature markets.
Key Takeaways
- NDC 12496-1212 (Opdivo) dominates the PD-1 inhibitor space with solid sales growth, driven by multiple approved indications.
- Patent expiration in 2028 poses a potential decline zone, encouraging biosimilar entry post-2029.
- Pricing is expected to decline steadily due to biosimilar competition, with a projection range from USD 4,000–USD 8,000 per dose.
- Revenue will remain resilient if indications expand and combination therapies succeed.
- Overall, market growth is fueled by new approvals and market penetration, but competitive pressures and patent expiration will impose pricing constraints.
FAQs
-
When does the patent for NDC 12496-1212 expire?
The last patent in the U.S. is expected to expire in 2028, with additional patent protections in certain markets extending into the late 2020s.
-
What are the main factors influencing Opdivo's price after patent expiry?
Biosimilar entry, market competition, pricing regulations, and healthcare reimbursement policies.
-
Which indications are likely to drive future growth for Opdivo?
Expansion into earlier lines of treatment, combination therapies, and new tumor types such as colorectal and gastric cancers.
-
How does biosimilar competition affect the overall PD-1 inhibitor market?
Biosimilars are expected to reduce prices by approximately 25%–50%, putting downward pressure on revenue for originator drugs like Opdivo.
-
What investments are necessary to sustain revenue growth?
Continued clinical trial development, expanding indications, and strategic licensing or partnerships to fortify market positioning.
References
[1] U.S. Food and Drug Administration. (2022). Patent expiration date for Opdivo. Retrieved from https://www.fda.gov/
[2] Evaluate Pharma. (2023). Oncology forecast report.
[3] IQVIA. (2022). Global oncology market analysis.
